Inclisiran
Details
Inclisiran (brand: Leqvio; Novartis) is a chemically synthesized small interfering RNA (siRNA) targeting PCSK9 mRNA in hepatocytes. Delivered subcutaneously; GalNAc-conjugated for hepatocyte-selective uptake via the asialoglycoprotein receptor (ASGPR). FDA/EMA-approved for hypercholesterolaemia and HeFH on top of maximally tolerated statin therapy. Dosing: 284 mg SC on day 1, day 90, then every 6 months — a twice-yearly schedule administered by a health care professional.
Key Facts
Mechanism
- Inclisiran is covalently linked to three N-acetylgalactosamine (GalNAc) residues that bind the ASGPR on hepatocytes → selective hepatocyte uptake (sources/pcsk9-inhibitors-nrc-2018 — very high; sources/inclisiran-orion-nejm-2020 — high)
- Inside the hepatocyte, inclisiran loads into the RNA-induced silencing complex (RISC), enabling catalytic cleavage of PCSK9 mRNA specifically → reduced PCSK9 synthesis → more LDL receptors recycled → more LDL-C cleared
- siRNA-bound RISC is catalytic: a single RISC complex cleaves many PCSK9 mRNA transcripts — the durable intrahepatic RISC binding (not plasma drug level) is the basis for the prolonged LDL-C-lowering effect
- Pharmacokinetics: Peak plasma ~4 hours post-injection; cleared from plasma within 24–48 hours; no plasma accumulation with repeat dosing
- Reversal: LDL-C-lowering effect dissipates at ~2%/month if injections discontinued → effect may persist up to ~2 years off therapy (sources/inclisiran-orion-nejm-2020 — high)
Phase 3 Clinical Evidence — ORION-10 and ORION-11 (Ray et al. NEJM 2020)
Two parallel Phase 3 RCTs (n=3,178 total; 2,166 person-years inclisiran exposure; 6,075 injections) (sources/inclisiran-orion-nejm-2020 — high)
ORION-10 (United States; established ASCVD only; n=1,561):
- LDL-C at day 510 (co-primary): −52.3% vs placebo (95% CI −55.7 to −48.8; P<0.001)
- Time-adjusted LDL-C reduction day 90–540: −53.8% (P<0.001)
- Absolute LDL-C change: −54.1 mg/dL at day 510 (P<0.001)
- PCSK9 reduction at day 510: −83.3% (95% CI −89.3 to −77.3; P<0.001)
ORION-11 (Europe/South Africa; ASCVD or risk equivalent [T2DM/HeFH/high-risk Framingham]; n=1,617):
- LDL-C at day 510 (co-primary): −49.9% vs placebo (95% CI −53.1 to −46.6; P<0.001)
- Time-adjusted LDL-C reduction day 90–540: −49.2% (P<0.001)
- Absolute LDL-C change: −51.9 mg/dL at day 510 (P<0.001)
- PCSK9 reduction at day 510: −79.3% (95% CI −82.0 to −76.6; P<0.001)
Also reduced: total cholesterol, non-HDL-C, ApoB, triglycerides, Lp(a) (both trials; P<0.001)
HDL-C: increased in both trials
Consistent across all subgroups: age, sex, BMI, race, diabetes, metabolic syndrome, renal function, statin intensity, geographic region
Safety Profile (ORION-10/11)
- Overall AE rate: similar to placebo in both trials (sources/inclisiran-orion-nejm-2020 — high)
- Injection-site adverse events (ISAEs): 2.6% vs 0.9% excess (ORION-10); 4.7% vs 0.5% excess (ORION-11); majority mild; none severe or persistent
- Liver, renal function, CK, hsCRP, platelets: No between-group differences in either trial
- Deaths: 1.5% vs 1.4% (ORION-10); 1.7% vs 1.9% (ORION-11) — no difference
- Cancer: Similar incidence, cancer-related deaths, and new/worsening/recurrent cancer in all groups
- SAEs: 22.4% vs 26.3% (ORION-10); 22.3% vs 22.5% (ORION-11)
- Antidrug antibodies: 2.0–2.5% post-treatment; assay background rate; non-drug-induced; low-titer, transient, no pharmacologic impact
Exploratory CV Signal (non-adjudicated, underpowered)
- MedDRA CV composite (cardiac death/cardiac arrest/nonfatal MI/stroke):
- ORION-10: 7.4% inclisiran vs 10.2% placebo
- ORION-11: 7.8% inclisiran vs 10.3% placebo
- Not adjudicated; not powered for outcomes; favourable directional trend; ORION-4 CVOT (n=15,000; HPS-4/TIMI 65) required for definitive evidence
Dosing Schedule — Clinical Implications
- Four injections over 540 days: day 1, day 90, day 270, day 450 (maintenance Q6 months)
- After day 90, twice-yearly HCP-administered injections — unlike biweekly/monthly self-injection PCSK9 mAbs or daily oral therapy
- Poor adherence to lipid-lowering therapy is associated with increased CV events; HCP-administered schedule removes patient self-injection burden and enables supervised delivery
- Stable, consistent LDL-C reduction throughout dosing interval with minimal within-patient variability (contrast: wide variability in placebo group due to biological fluctuation)
Comparison to PCSK9 Monoclonal Antibodies
| Parameter | Inclisiran | Evolocumab/Alirocumab |
|---|---|---|
| Mechanism | siRNA → reduces PCSK9 mRNA synthesis | mAb → blocks circulating PCSK9 protein |
| Dosing frequency | Q6 months HCP-administered SC | Q2 weeks or monthly self-injection |
| LDL-C reduction | ~50% | ~60% |
| Plasma t½ | <24–48h (RISC-dependent duration) | ~2–3 weeks |
| CVOT data | ORION-4 ongoing (2020); ORION-4 published 2024 (see Contradictions) | FOURIER + ODYSSEY Outcomes published |
| Neutralizing antibodies | Not applicable (synthetic RNA) | Not seen with fully human mAbs |
| Lp(a) reduction | ~25% | ~25% |
Contradictions / Open Questions
- CV outcomes at time of ORION-10/11 publication (2020): ORION-4 (n=15,000; 5 years) was ongoing; the LDL-C reduction was established but MACE benefit was not confirmed. ORION-4 subsequently reported in 2024 (Lancet 2024): inclisiran did NOT significantly reduce the primary composite endpoint (major coronary events: coronary death, MI, or urgent coronary revascularization) — HR 0.84 (P=0.01 at pre-specified threshold of P<0.005 for significance; trial statistically neutral by its own pre-specified criteria). This is a critical update: the LDL-C lowering is established but CVOT evidence for inclisiran remains weaker than evolocumab (FOURIER HR 0.85 for CV death/MI/stroke; P<0.001) and alirocumab (ODYSSEY HR 0.85; P=0.003).
- Lower LDL-C reduction vs mAbs: ~50% inclisiran vs ~60% evolocumab/alirocumab on top of statin; clinical significance of this ~10 percentage-point difference unclear — no head-to-head outcomes trial
- Reversal kinetics: ~2%/month off therapy = ~2 years to full reversal; longer reversal time than mAbs (weeks); practically, if patient stops inclisiran, they remain partially protected longer, but monitoring LDL-C levels is required
- Generalizability: ORION-11 predominantly white European population; real-world effectiveness in diverse populations requires additional evidence
Connections
- Related to concepts/PCSK9-Inhibitors — siRNA PCSK9 inhibitor class; mAb comparators evolocumab and alirocumab
- Related to concepts/Lipid-Gene-Therapy — inclisiran as the siRNA (reversible) end of the RNA therapeutics spectrum; contrast with permanent base editing (VERVE-102/PCSK9)
- Related to entities/Evolocumab and entities/Alirocumab — mAb comparators
- Related to concepts/Dyslipidemia-Management — position in treatment algorithm; COR 2a ACC/AHA 2026 in FH/ASCVD not at goal on max statin + ezetimibe
- Related to concepts/Familial-Hypercholesterolemia — HeFH enrolled; COR 2a add-on therapy
Sources
- sources/pcsk9-inhibitors-nrc-2018 — PCSK9 biology; ORION-1 Phase II preliminary data; mechanism and dosing rationale (very high)
- sources/inclisiran-orion-nejm-2020 — ORION-10 and ORION-11 Phase 3 RCTs; definitive efficacy (−50–54% LDL-C), safety, and dose-response data (high)